Opendata, web and dolomites

GT-GM1 SIGNED

Ex vivo gene therapy for GM1-gangliosidosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GT-GM1 project word cloud

Explore the words cloud of the GT-GM1 project. It provides you a very rough idea of what is the project "GT-GM1" about.

association    vivo    conventional    severe    infantile    disorder    reconstitution    mediating    secondary    omim    anticipate    genome    recessive    hematopoietic    route    caused    genetically    correction    ex    enzyme    death    proof    transfer    nature    direct    therapeutic    administered    animal    intravenous    hydrolase    local    inflammation    lentiviral    alone    sustained    gt    efficacious    mechanisms    beta    230500    autosomal    model    mutations    undegraded    therapies    individual    dysphagia    storage    deep    rapid    therapy    multiple    lysosomal    copies    disease    manifestations    lsds    cell    gm    expression    hypothesis    ventricles    nervous    murine    myeloid    hypotonia    lateral    possibly    molecular    cns    seizures    delay    encoding    hspcs    mice    neurodegenerative    performed    genomics    progression    transplanted    neurodevelopmental    basis    damage    neuroprotective    preventing    gangliosidosis    inspire    life    generate    ameliorating    rare    cells    combining    clinical    gm1    progenitor    strategy    symptoms    effect    glb1    successfully    optimized    elucidate    administration    modified    central    galactosidase    gene    brain    delivered    metabolites    stem   

Project "GT-GM1" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI PADOVA 

Organization address
address: VIA 8 FEBBRAIO 2
city: PADOVA
postcode: 35122
website: www.unipd.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 171˙473 €
 EC max contribution 171˙473 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2022-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI PADOVA IT (PADOVA) coordinator 171˙473.00

Map

 Project objective

'GM-gangliosidosis (OMIM #230500) is a rare, autosomal recessive, neurodegenerative Lysosomal Storage Disorder. It is caused by mutations in the GLB1 gene, encoding the lysosomal hydrolase β-galactosidase. Infantile GM1-gangliosidosis is characterized by neurodevelopmental delay, hypotonia, dysphagia, seizures and death by 3 years of life. Due to the rapid progression and severe nature of this disease, which involves storage of undegraded metabolites and secondary mechanisms of cell damage, correction requires a rapid and robust enzyme delivery to the whole central nervous system (CNS), possibly associated to reduction of local inflammation. Here we propose an ex vivo gene therapy (GT) strategy aimed at preventing or ameliorating the symptoms of the disease in the murine model. Multiple copies of GLB1, alone or in association with a neuroprotective factor, will be delivered ex vivo to hematopoietic stem/progenitor cells by lentiviral gene transfer to determine a sustained and robust expression of the therapeutic enzyme in the CNS of transplanted mice. Genetically modified HSPCs will be administered by a novel approach combining the conventional intravenous route with direct administration into the brain lateral ventricles, to anticipate the myeloid reconstitution in the brain and possibly the therapeutic effect. Our working hypothesis is that this optimized GT strategy could successfully control disease manifestations in the animal model. Moreover, a deep genome-wide genomics analysis will be performed on individual brain cells to elucidate the molecular mechanisms at the basis of the disease and mediating the therapeutic effect. The study will generate a proof of concept for a future clinical development of an efficacious ex vivo GT for infantile GM1-gangliosidosis and will inspire the development of therapies for other LSDs. '

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GT-GM1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GT-GM1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Photonic Radar (2019)

Implementation of Long Reach Hybrid Photonic Radar System and convergence over FSO and PON Networks

Read More  

CORRELATION (2020)

Characterization and prediction of service-level traffic for future sliced mobile network

Read More  

VINCI (2020)

The Value of Information and Choice to Improve Control.

Read More